Combinations of iadademstat for cancer therapy
AssigneeOryzon Genomics, S.A.
InventorFilippo CICERI
Life of this patent
Estimating the term…
Abstract
The present invention relates to combinations, methods and compositions for the treatment of cancer comprising the administration of iadademstat in combination with PD(L)1 inhibitor.
Claims34
A combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor.
A combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor for use in therapy.
A combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor for use in the treatment of a disease.
A combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor for use in the treatment of cancer.
Iadademstat, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of cancer in combination with a PD(L)1 inhibitor.
A PD(L)1 inhibitor for use in the treatment of cancer in combination with iadademstat or a pharmaceutically acceptable salt or solvate thereof.
A method for treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor.
A method for treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a therapeutically effective amount of a PD(L)1 inhibitor.
Use of iadademstat, or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of cancer to be used in combination with a PD(L)1 inhibitor.
Use of a PD(L)1 inhibitor for the manufacture of a medicament for the treatment of cancer to be used in combination with iadademstat or a pharmaceutically acceptable salt or solvate thereof.
Use of a combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor for the manufacture of a medicament for the treatment of cancer.
Use of a combination comprising iadademstat, or a pharmaceutically acceptable salt or solvate thereof, and a PD(L)1 inhibitor for the treatment of cancer.
Use of iadademstat, or a pharmaceutically acceptable salt or solvate thereof, for the treatment of cancer in combination with a PD(L)1 inhibitor.
Use of a PD(L)1 inhibitor for the treatment of cancer in combination with iadademstat or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.